Cell Therapy News Volume 21.32 | Sep 14 2020

    By
    Justin.choi
    -
    0
    73







    CTN 21.32 | Sept 14 2020


    Cell Therapy News by STEMCELL Technologies
    Vol. 21.32 – 14 September, 2020
    TOP STORY

    Islet
    Transplantation in the Subcutaneous Space Achieves Long-Term Euglycemia in Preclinical Models of Type 1 Diabetes

    Scientists report the successful subcutaneous transplantation of pancreatic islets admixed with a device-free islet viability matrix, resulting in long-term euglycemia in diverse immune-competent and immuno-incompetent animal models.
    [Nature Metabolism]

    Abstract

    Dr. Jackie Damen discusses why the CFU assay should be a vital part of your cell therapy workflow in this on-demand webinar.
    PUBLICATIONSRanked by the impact factor of the journal

    A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia

    Researchers assessed the performance of the knowledge bank in guiding hematopoietic stem cell transplantation decision in first complete remission in 656 acute myeloid leukemia patients younger than 60 years from the ALFA-0702 trial.
    [Blood]

    Abstract

    Favorable Outcomes of COVID-19 in Recipients of Hematopoietic Cell Transplantation

    In this study of recipients of allogeneic and autologous hematopoietic cell transplant and CD19-directed chimeric antigen receptor T cell therapy at Memorial Sloan Kettering Cancer Center, scientists aimed to identify clinical variables associated with COVID-19 severity and assess lymphocyte populations.
    [Journal of Clinical Investigation]

    AbstractFull Article

    CSPG4-Specific
    CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft Tissue Sarcoma Histotypes

    The functional activity of chondroitin sulfate proteoglycan 4 (CSPG4)-CAR-redirected cytokine-induced killer lymphocytes (CAR.CIK) was explored in vitro, in 2D and 3D soft tissue sarcoma (STS) cultures, and in three in vivo STS xenograft models.
    [Clinical Cancer Research]

    Abstract

    PD1
    Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer

    Scientists studied the tumor targeting efficacy and T cell dynamics of mono- and combination treatments of intercellular adhesion molecule 1-targeting CAR T cells and anti-PD1 antibody in a xenograft model of anaplastic thyroid cancer.
    [Clinical Cancer Research]

    Abstract

    Comparing
    Measures of Hematologic Response after High-Dose Melphalan and Stem Cell Transplantation in AL Amyloidosis

    The authors evaluated overall survival in 340 patients treated with high-dose melphalan and stem cell transplantation (SCT). Of 305 patients evaluable six months after SCT, 90 achieved hemCR, 132 difference in free light chains
    [Blood Cancer Journal]

    Full Article

    In Vivo
    HSC Gene Therapy Using a Bi-Modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model

    Investigators generated a HDAd5/35++ adenovirus vector and tested it in vitro and after in vivo hematopoietic stem cell/progenitor transduction in “healthy” CD46/β-YAC mice and in a Sickle Cell Disease mouse model.
    [Molecular Therapy]

    AbstractGraphical Abstract

    Mesenchymal
    Stem Cells Derived Extracellular Vesicles Improve Behavioral and Biochemical Deficits in a Phencyclidine Model of Schizophrenia

    Researchers assessed the feasibility of intranasal delivery of mesenchymal stem cell-derived-extracellular vesicles to alleviate schizophrenia-like behaviors in a phencylidine model of schizophrenia.
    [Translational Psychiatry]

    Full Article

    Carfilzomib
    Combined with Cyclosporine and Methotrexate for the Prevention of Graft-versus-Host Disease after Allogeneic Stem-Cell Transplantation from Unrelated Donors

    Investigators explored the addition of carfilzomib, a second-generation proteasome inhibitor to cyclosporine/methotrexate backbone in 26 patients after stem cell transplantation from unrelated donors.
    [Bone Marrow Transplantation]

    Abstract

    Wilm’s
    Tumor 1-Guided Preemptive Treatment with Hypomethylating Agents for Molecular Relapse of AML and MDS after Allogeneic Transplantation

    As Wilm’s Tumor 1 (WT1)– expression has proven to serve as broadly applicable, sensitive and specific minimal residual disease (MRD) marker, investigators measured WT1-expression in 35 acute myeloid leukemiaand myelodysplastic syndromes patients using a standardized assay for the guidance of therapy with hypomethylating agents and donor lymphocyte infusions.
    [Bone Marrow Transplantation]

    Abstract

    Administration
    of Cardiac Mesenchymal Cells Modulates Innate Immunity in the Acute Phase of Myocardial Infarction in Mice

    Researchers evaluated the consequences of cardiac mesenchymal cell administration on post myocardial infarction immune responses in vivo and paracrine-mediated immune cell function in vitro.
    [Scientific Reports]

    Full Article

    Reproducible
    Production and Image-Based Quality Evaluation of Retinal Pigment Epithelium Sheets from Human Induced Pluripotent Stem Cells

    Scientists found that stepwise treatment with six signaling pathway inhibitors along with nicotinamide increased retinal pigment epithelial (RPE) differentiation efficiency, enabling the RPE sheet generation at high purity without manual selection.
    [Scientific Reports]

    Full Article


    Start Fast. Finish Faster. Streamline your assays with purified human primary cells from STEMCELL Technologies. View products now.
    REVIEWS

    Potential
    of Mesenchymal Stem Cells as Topical Immunomodulatory Cell Therapies for Ocular Surface Inflammatory Disorders

    Researchers highlight considerations, including whether the source of mesenchymal stem cell (MSC) isolation impacts the efficacy and safety of the therapy, in addition to assessing the feasibility of MSC topical application to the cornea and ocular surface through analysis of potential scaffolds and cell carriers for application to the eye.
    [Stem Cells Translational Medicine]

    Full Article

    INDUSTRY AND POLICY NEWS

    Commission
    Charts Narrow Path for Editing Human Embryos

    An international committee has concluded that gene-editing methods, despite substantial improvements, are still far from mature enough to safely introduce heritable DNA modifications into human embryos.
    [ScienceInsider]

    Editorial

    Autolus
    Therapeutics to Further Expand Operations at the CGT Catapult Manufacturing Centre to Enable Commercial Manufacture of CAR-T Cell Therapies

    Autolus and CGT Catapult collaborated to achieve approval for commercial manufacture of CAR-T cell therapies from the CGT Catapult manufacturing centre. The collaboration will enable the UK company to expand further and contribute to the global competitiveness of the UK cell and gene therapy industry.
    [CGT Catapult ]

    Press Release

    FEATURED EVENT

    Channels
    in Context: Structure and Function of Ion Channels in Macromolecular Complexes and Native Cells

    Sep 7 – 11, 2022
    Woods Hole, Massachusetts, United States


    > See All Events

    JOB OPPORTUNITIES

    PhD
    Student – Topical Gene Therapy

    The University of British Columbia – Vancouver, British Columbia, Canada


    Postdoctoral Scholar – Biomedical Engineering in Regenerative Medicine

    Pennsylvania State University – Philadelphia, Pennsylvania, United States

    Research Fellow – Multiple Myeloma

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Research
    Fellow Position – Neural Cell Therapy

    Nanyang Technological University – Singapore, Singapore

    Postdoctoral
    Fellow – Immunotherapy

    Roswell Park Center for Immunotherapy – Buffalo, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Cell Therapy News
    Archives Contact Us
    Cell Therapy News Twitter